C-Kit SCF R is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily and CSF-1 PDGF receptor subfamily. SCF R expression on mast cells enables them to infiltrate SCF-secreting tumors where they promote tumor growth and induce local immune suppression. SCF R is up-regulated on dendritic cells by Th2-orTh17-biasing stimuli, and it is required for subsequent dendritic cell induction of Th2 and Th17 responses. SCF R protects vascular smooth muscle cells from apoptosis and assists in the recovery of cardiac function following myocardial infarction.
The c-kit proto-oncogen (CD117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages. CD117 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 56.63 kDa and the accession number is P05532-2.
The c-kit proto-oncogen (CD117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages. CD117 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 58.60 kDa and the accession number is P10721-2.
The c-kit proto-oncogen (CD117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages.
c-Kit Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82 kDa and the accession number is P10721-2.
c-Kit Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82.5 kDa and the accession number is P05532-1.
c-Kit Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 57 kDa and the accession number is P05532-1.
c-Kit Protein, Human, Recombinant (aa 50-190, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 17.9 kDa and the accession number is P10721-1.
c-Kit Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 58.50 kDa and the accession number is P10721-2.
c-Kit Protein, Human, Recombinant (aa 540-972, His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 76.8 kDa and the accession number is P10721-2.
c-Kit Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 56.7 kDa and the accession number is P10721-2.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.